挑战经导管优先策略:经导管或外科主动脉瓣置换术后再行外科主动脉瓣置换术
该研究分析2011至2024年1024例主动脉瓣再手术患者,其中TAVR后SAVR 127例、SAVR后SAVR 897例。在孤立SAVR±CABG亚组中,TAVR-SAVR组尽管更多患者无既往胸骨切开且体外循环时间更短,但手术死亡率显著高于SAVR-SAVR组(12.3% vs 1.1%,P < .001)。倾向性评分匹配后结论一致,提示对预期寿命超过TAVR瓣膜耐久性的患者应重新考虑经导管优先策略。
要点
- TAVR-SAVR占所有主动脉瓣再手术比例从2011-2012年0%升至2024年31.3%。
- 孤立SAVR±CABG亚组中TAVR-SAVR手术死亡率12.3%,显著高于SAVR-SAVR的1.1%。
- 匹配后TAVR-SAVR手术死亡率仍更高(12.0% vs 1.1%,P = .008),复合并发症率也更高。
核心结论
- TAVR-SAVR病例数增加,预计2029年可能超过SAVR-SAVR病例。
- 匹配后TAVR-SAVR患者行SAVR±CABG结局仍更差,而SAVR-SAVR策略极其安全。
- 对预期寿命超过TAVR瓣膜耐久性的患者,应重新考虑经导管优先策略。
研究设计与样本
- 回顾性队列研究,纳入2011至2024年1024例连续主动脉瓣再手术患者。
- TAVR-SAVR组127例,SAVR-SAVR组897例;孤立SAVR±CABG亚组分别为57例和447例。
- 采用1:2倾向性评分匹配,匹配后TAVR-SAVR 50例、SAVR-SAVR 93例。
主要发现
- TAVR-SAVR占所有主动脉瓣再手术比例从2011-2012年0%增至2024年31.3%。
- TAVR-SAVR组患者更年长、合并症和心衰负担更重,STS预测死亡风险更高。
- 61.2%的TAVR-SAVR患者无既往胸骨切开,体外循环和主动脉阻断时间更短。
- TAVR-SAVR组手术死亡率12.3%,SAVR-SAVR组1.1%(P < .001)。
- 匹配后TAVR-SAVR组手术死亡率12.0%,SAVR-SAVR组1.1%(P = .008),复合并发症率更高。
关键数值与推荐
- SAVR-SAVR队列观察值与预期死亡率比为0.33(95%置信区间0.11-0.76)。
- TAVR-SAVR占所有主动脉瓣再手术比例2024年为31.3%。
- 孤立SAVR±CABG亚组中TAVR-SAVR手术死亡率12.3%,SAVR-SAVR为1.1%(P < .001)。
- 匹配后TAVR-SAVR手术死亡率12.0%,SAVR-SAVR为1.1%(P = .008)。
临床怎么用
- 对预期寿命超过TAVR瓣膜耐久性的主动脉瓣疾病患者,应重新评估经导管优先策略。
- TAVR后需再行SAVR的患者手术风险高,术前应充分评估并告知。
- SAVR后再次SAVR在选定患者中极其安全,观察值与预期死亡率比低。
局限性
- 为单中心回顾性研究,可能存在选择偏倚。
- TAVR-SAVR组样本量较小(127例,匹配后50例)。
- 高队列异质性可能影响比较分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aortic valve reoperations after transcatheter aortic valve replacement (TAVR) are increasing. However, concerns persist regarding poor clinical outcomes, whereas high cohort heterogeneity has historically precluded meaningful comparative analyses. METHODS: We identified 1024 consecutive patients who underwent surgical aortic valve replacement (SAVR) after either TAVR (TAVR-SAVR; n = 127) or SAVR (SAVR-SAVR; n = 897) between 2011 and 2024. Among these, patients undergoing isolated SAVR ± coronary artery bypass grafting were included: 57 in the TAVR-SAVR group and 447 in the SAVR-SAVR group. RESULTS: The proportion of TAVR-SAVR among all aortic valve reoperations increased from 0% in 2011-2012 to 31.3% in 2024. Patients in the TAVR-SAVR group were older, exhibited greater comorbidity and heart failure burden, and had greater Society of Thoracic Surgeons Predicted Risk of Mortality. Despite 61.2% of TAVR-SAVR patients lacking previous sternotomy with shorter cardiopulmonary bypass and aortic crossclamp times, they demonstrated significantly greater operative mortality (12.3% vs 1.1%, P < .001). In contrast, the SAVR-SAVR cohort exhibited a remarkably low observed-to-expected mortality ratio of 0.33 (95% confidence interval, 0.11-0.76). After 1:2 propensity score matching (50 TAVR-SAVR vs 93 SAVR-SAVR patients), the TAVR-SAVR group continued to show greater operative mortality (12.0% vs 1.1%, P = .008) and greater composite complication rates. CONCLUSIONS: TAVR-SAVR cases are increasing and may surpass SAVR-SAVR cases by 2029. Despite matching, patients undergoing SAVR ± coronary artery bypass grafting showed worse outcomes in TAVR-SAVR, whereas a SAVR-SAVR strategy was extremely safe. Reconsideration of the TAVR-first strategy is warranted for patients expected to outlive the durability of TAVR prostheses.
引用
- Fukuhara S, Ling C, Patel HJ, et al. Challenging the transcatheter-first paradigm: Redo surgical aortic valve replacement after previous transcatheter or surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2025. PMID: 40840708. doi:10.1016/j.jtcvs.2025.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。